Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 20 entries
Sorted by: Best Match Show Resources per page
Granulocyte colony-stimulating factor inhibits CXCR4/SDF-1α signaling and overcomes stromal-mediated drug resistance in the HL-60 cell line.

Experimental and therapeutic medicine

Sheng X, Zhong H, Wan H, Zhong J, Chen F.
PMID: 27347068
Exp Ther Med. 2016 Jul;12(1):396-404. doi: 10.3892/etm.2016.3268. Epub 2016 Apr 20.

Combining cytarabine, aclarubicin and granulocyte colony-stimulating factor (G-CSF) has demonstrated marked efficacy in the treatment of elderly and relapsed/refractory patients with acute myeloid leukemia (AML); however, the role of G-CSF remains poorly understood. The present study aimed to investigate...

Cite
Sheng X, Zhong H, Wan H, et al. Granulocyte colony-stimulating factor inhibits CXCR4/SDF-1α signaling and overcomes stromal-mediated drug resistance in the HL-60 cell line. Exp Ther Med. 2016;12(1):396-404doi: 10.3892/etm.2016.3268.
Sheng, X., Zhong, H., Wan, H., Zhong, J., & Chen, F. (2016). Granulocyte colony-stimulating factor inhibits CXCR4/SDF-1α signaling and overcomes stromal-mediated drug resistance in the HL-60 cell line. Experimental and therapeutic medicine, 12(1), 396-404. https://doi.org/10.3892/etm.2016.3268
Sheng, Xianfu, et al. "Granulocyte colony-stimulating factor inhibits CXCR4/SDF-1α signaling and overcomes stromal-mediated drug resistance in the HL-60 cell line." Experimental and therapeutic medicine vol. 12,1 (2016): 396-404. doi: https://doi.org/10.3892/etm.2016.3268
Sheng X, Zhong H, Wan H, Zhong J, Chen F. Granulocyte colony-stimulating factor inhibits CXCR4/SDF-1α signaling and overcomes stromal-mediated drug resistance in the HL-60 cell line. Exp Ther Med. 2016 Jul;12(1):396-404. doi: 10.3892/etm.2016.3268. Epub 2016 Apr 20. PMID: 27347068; PMCID: PMC4906714.
Copy Download .nbib Format: NLM
Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report.

Oncology letters

Deng Q, Li JY, Liu PJ, Zhao MF.
PMID: 25663885
Oncol Lett. 2015 Mar;9(3):1217-1220. doi: 10.3892/ol.2015.2870. Epub 2015 Jan 13.

Despite advances in the treatment of acute myeloid leukemia (AML) in recent years, the outcome of elderly AML patients with antecedent hematological disorders remains unsatisfactory. The present study describes a case of complete remission in an elderly patient with...

Cite
Deng Q, Li JY, Liu PJ, et al. Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report. Oncol Lett. 2015;9(3):1217-1220doi: 10.3892/ol.2015.2870.
Deng, Q., Li, J. Y., Liu, P. J., & Zhao, M. F. (2015). Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report. Oncology letters, 9(3), 1217-1220. https://doi.org/10.3892/ol.2015.2870
Deng, Qi, et al. "Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report." Oncology letters vol. 9,3 (2015): 1217-1220. doi: https://doi.org/10.3892/ol.2015.2870
Deng Q, Li JY, Liu PJ, Zhao MF. Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report. Oncol Lett. 2015 Mar;9(3):1217-1220. doi: 10.3892/ol.2015.2870. Epub 2015 Jan 13. PMID: 25663885; PMCID: PMC4315126.
Copy Download .nbib Format: NLM
Immunological effects of a low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor priming regimen on a mouse leukemia model.

Oncology letters

Chen J, Yang N, Liu H, Yao H, Wang J, Yang Y, Zhang W.
PMID: 30127892
Oncol Lett. 2018 Sep;16(3):3022-3028. doi: 10.3892/ol.2018.9018. Epub 2018 Jun 25.

The low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor (G-CSF) (CAG) priming regimen is an effective treatment for patients with relapsed or refractory acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS). G-CSF influences the bone marrow microenvironment (BMM) by...

Cite
Chen J, Yang N, Liu H, et al. Immunological effects of a low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor priming regimen on a mouse leukemia model. Oncol Lett. 2018;16(3):3022-3028doi: 10.3892/ol.2018.9018.
Chen, J., Yang, N., Liu, H., Yao, H., Wang, J., Yang, Y., & Zhang, W. (2018). Immunological effects of a low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor priming regimen on a mouse leukemia model. Oncology letters, 16(3), 3022-3028. https://doi.org/10.3892/ol.2018.9018
Chen, Jinqiu, et al. "Immunological effects of a low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor priming regimen on a mouse leukemia model." Oncology letters vol. 16,3 (2018): 3022-3028. doi: https://doi.org/10.3892/ol.2018.9018
Chen J, Yang N, Liu H, Yao H, Wang J, Yang Y, Zhang W. Immunological effects of a low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor priming regimen on a mouse leukemia model. Oncol Lett. 2018 Sep;16(3):3022-3028. doi: 10.3892/ol.2018.9018. Epub 2018 Jun 25. PMID: 30127892; PMCID: PMC6096276.
Copy Download .nbib Format: NLM
Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine.

Anti-cancer drugs

Sun J, Ning S, Feng R, Li J, Wang T, Xing B, Zhu X, Zhao Y, Pei L, Liu H.
PMID: 34459465
Anticancer Drugs. 2022 Jan 01;33(1):e813-e817. doi: 10.1097/CAD.0000000000001228.

Some previous researches raised the possibility of a novel acute myeloid leukemia (AML) entity presenting cup-like cytomorphology with mutations of both FLT3 and NPM1 or one of them. However, the clinical implications of this subtype remain unknown. We describe...

Cite
Sun J, Ning S, Feng R, et al. Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine. Anticancer Drugs. 2022;33(1):e813-e817doi: 10.1097/CAD.0000000000001228.
Sun, J., Ning, S., Feng, R., Li, J., Wang, T., Xing, B., Zhu, X., Zhao, Y., Pei, L., & Liu, H. (2022). Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine. Anti-cancer drugs, 33(1), e813-e817. https://doi.org/10.1097/CAD.0000000000001228
Sun, Jie, et al. "Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine." Anti-cancer drugs vol. 33,1 (2022): e813-e817. doi: https://doi.org/10.1097/CAD.0000000000001228
Sun J, Ning S, Feng R, Li J, Wang T, Xing B, Zhu X, Zhao Y, Pei L, Liu H. Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine. Anticancer Drugs. 2022 Jan 01;33(1):e813-e817. doi: 10.1097/CAD.0000000000001228. PMID: 34459465; PMCID: PMC8670335.
Copy Download .nbib Format: NLM
Analysis of efficacy, safety and prognostic factors of DAC-HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia.

Molecular and clinical oncology

Wang L, Li C, Xu F, Cao F, Zhang B, Wang J, Wang S, Chen L, Li N, Liao C, Liu H.
PMID: 34790353
Mol Clin Oncol. 2021 Dec;15(6):269. doi: 10.3892/mco.2021.2431. Epub 2021 Nov 01.

Hematopoietic stem cell transplantation (HSCT) is generally considered as the only effective treatment for children with relapsed/refractory (R/R) acute myeloid leukemia (AML). Achieving remission prior to HSCT affects the efficacy of the procedure and patient survival; therefore, induction therapy...

Cite
Wang L, Li C, Xu F, et al. Analysis of efficacy, safety and prognostic factors of DAC-HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia. Mol Clin Oncol. 2021;15(6):269doi: 10.3892/mco.2021.2431.
Wang, L., Li, C., Xu, F., Cao, F., Zhang, B., Wang, J., Wang, S., Chen, L., Li, N., Liao, C., & Liu, H. (2021). Analysis of efficacy, safety and prognostic factors of DAC-HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia. Molecular and clinical oncology, 15(6), 269. https://doi.org/10.3892/mco.2021.2431
Wang, Liang, et al. "Analysis of efficacy, safety and prognostic factors of DAC-HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia." Molecular and clinical oncology vol. 15,6 (2021): 269. doi: https://doi.org/10.3892/mco.2021.2431
Wang L, Li C, Xu F, Cao F, Zhang B, Wang J, Wang S, Chen L, Li N, Liao C, Liu H. Analysis of efficacy, safety and prognostic factors of DAC-HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia. Mol Clin Oncol. 2021 Dec;15(6):269. doi: 10.3892/mco.2021.2431. Epub 2021 Nov 01. PMID: 34790353; PMCID: PMC8591692.
Copy Download .nbib Format: NLM
Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine.

Anti-cancer drugs

Sun J, Ning S, Feng R, Li J, Wang T, Xing B, Zhu X, Zhao Y, Pei L, Liu H.
PMID: 34459465
Anticancer Drugs. 2022 Jan 01;33(1):e813-e817. doi: 10.1097/CAD.0000000000001228.

Some previous researches raised the possibility of a novel acute myeloid leukemia (AML) entity presenting cup-like cytomorphology with mutations of both FLT3 and NPM1 or one of them. However, the clinical implications of this subtype remain unknown. We describe...

Cite
Sun J, Ning S, Feng R, et al. Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine. Anticancer Drugs. 2022;33(1):e813-e817doi: 10.1097/CAD.0000000000001228.
Sun, J., Ning, S., Feng, R., Li, J., Wang, T., Xing, B., Zhu, X., Zhao, Y., Pei, L., & Liu, H. (2022). Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine. Anti-cancer drugs, 33(1), e813-e817. https://doi.org/10.1097/CAD.0000000000001228
Sun, Jie, et al. "Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine." Anti-cancer drugs vol. 33,1 (2022): e813-e817. doi: https://doi.org/10.1097/CAD.0000000000001228
Sun J, Ning S, Feng R, Li J, Wang T, Xing B, Zhu X, Zhao Y, Pei L, Liu H. Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine. Anticancer Drugs. 2022 Jan 01;33(1):e813-e817. doi: 10.1097/CAD.0000000000001228. PMID: 34459465.
Copy Download .nbib Format: NLM
Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine.

Anti-cancer drugs

Sun J, Ning S, Feng R, Li J, Wang T, Xing B, Zhu X, Zhao Y, Pei L, Liu H.
PMID: 34459465
Anticancer Drugs. 2021 Aug 27; doi: 10.1097/CAD.0000000000001228. Epub 2021 Aug 27.

Some previous researches raised the possibility of a novel acute myeloid leukemia (AML) entity presenting cup-like cytomorphology with mutations of both FLT3 and NPM1 or one of them. However, the clinical implications of this subtype remain unknown. We describe...

Cite
Sun J, Ning S, Feng R, et al. Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine. Anticancer Drugs. 2021;doi: 10.1097/CAD.0000000000001228.
Sun, J., Ning, S., Feng, R., Li, J., Wang, T., Xing, B., Zhu, X., Zhao, Y., Pei, L., & Liu, H. (2021). Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine. Anti-cancer drugs, . https://doi.org/10.1097/CAD.0000000000001228
Sun, Jie, et al. "Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine." Anti-cancer drugs vol. (2021). doi: https://doi.org/10.1097/CAD.0000000000001228
Sun J, Ning S, Feng R, Li J, Wang T, Xing B, Zhu X, Zhao Y, Pei L, Liu H. Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine. Anticancer Drugs. 2021 Aug 27; doi: 10.1097/CAD.0000000000001228. Epub 2021 Aug 27. PMID: 34459465.
Copy Download .nbib Format: NLM
Successful management of therapy-related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil.

Clinical case reports

Nakako S, Takakuwa T, Ichimura H, Okamura H, Nanno S, Nishimoto M, Nakashima Y, Koh H, Hino M, Nakamae H.
PMID: 34194799
Clin Case Rep. 2021 Jun 24;9(6):e04298. doi: 10.1002/ccr3.4298. eCollection 2021 Jun.

A 55-year-old man was diagnosed with therapy-related chronic myelomonocytic leukemia (t-CMML) after exposure to tegafur/gimeracil/oteracil. Although he was refractory to hydroxyurea and low-dose cytarabine, combination therapy with cytarabine, aclarubicin and azacitidine (CA-AZA) provided good disease control, and he underwent...

Cite
Nakako S, Takakuwa T, Ichimura H, et al. Successful management of therapy-related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil. Clin Case Rep. 2021;9(6):e04298doi: 10.1002/ccr3.4298.
Nakako, S., Takakuwa, T., Ichimura, H., Okamura, H., Nanno, S., Nishimoto, M., Nakashima, Y., Koh, H., Hino, M., & Nakamae, H. (2021). Successful management of therapy-related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil. Clinical case reports, 9(6), e04298. https://doi.org/10.1002/ccr3.4298
Nakako, Soichiro, et al. "Successful management of therapy-related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil." Clinical case reports vol. 9,6 (2021): e04298. doi: https://doi.org/10.1002/ccr3.4298
Nakako S, Takakuwa T, Ichimura H, Okamura H, Nanno S, Nishimoto M, Nakashima Y, Koh H, Hino M, Nakamae H. Successful management of therapy-related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil. Clin Case Rep. 2021 Jun 24;9(6):e04298. doi: 10.1002/ccr3.4298. eCollection 2021 Jun. PMID: 34194799; PMCID: PMC8223688.
Copy Download .nbib Format: NLM
Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma.

Investigational new drugs

Saeed MEM, Kadioglu O, Greten HJ, Yildirim A, Mayr K, Wenz F, Giordano FA, Efferth T.
PMID: 33313992
Invest New Drugs. 2021 Jun;39(3):670-685. doi: 10.1007/s10637-020-01037-7. Epub 2020 Dec 12.

Background Precision medicine and drug repurposing are attractive strategies, especially for tumors with worse prognosis. Glioblastoma is a highly malignant brain tumor with limited treatment options and short survival times. We identified novel BRAF (47-438del) and PIK3R1 (G376R) mutations...

Cite
Saeed MEM, Kadioglu O, Greten HJ, et al. Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma. Invest New Drugs. 2020;39(3):670-685doi: 10.1007/s10637-020-01037-7.
Saeed, M. E. M., Kadioglu, O., Greten, H. J., Yildirim, A., Mayr, K., Wenz, F., Giordano, F. A., & Efferth, T. (2021). Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma. Investigational new drugs, 39(3), 670-685. https://doi.org/10.1007/s10637-020-01037-7
Saeed, Mohamed E M, et al. "Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma." Investigational new drugs vol. 39,3 (2021): 670-685. doi: https://doi.org/10.1007/s10637-020-01037-7
Saeed MEM, Kadioglu O, Greten HJ, Yildirim A, Mayr K, Wenz F, Giordano FA, Efferth T. Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma. Invest New Drugs. 2021 Jun;39(3):670-685. doi: 10.1007/s10637-020-01037-7. Epub 2020 Dec 12. PMID: 33313992; PMCID: PMC8068653.
Copy Download .nbib Format: NLM
Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine.

Anti-cancer drugs

Sun J, Ning S, Feng R, Li J, Wang T, Xing B, Zhu X, Zhao Y, Pei L, Liu H.
PMID: 34459465
Anticancer Drugs. 2022 Jan 01;33(1):e813-e817. doi: 10.1097/CAD.0000000000001228.

Some previous researches raised the possibility of a novel acute myeloid leukemia (AML) entity presenting cup-like cytomorphology with mutations of both FLT3 and NPM1 or one of them. However, the clinical implications of this subtype remain unknown. We describe...

Cite
Sun J, Ning S, Feng R, et al. Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine. Anticancer Drugs. 2022;33(1):e813-e817doi: 10.1097/CAD.0000000000001228.
Sun, J., Ning, S., Feng, R., Li, J., Wang, T., Xing, B., Zhu, X., Zhao, Y., Pei, L., & Liu, H. (2022). Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine. Anti-cancer drugs, 33(1), e813-e817. https://doi.org/10.1097/CAD.0000000000001228
Sun, Jie, et al. "Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine." Anti-cancer drugs vol. 33,1 (2022): e813-e817. doi: https://doi.org/10.1097/CAD.0000000000001228
Sun J, Ning S, Feng R, Li J, Wang T, Xing B, Zhu X, Zhao Y, Pei L, Liu H. Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine. Anticancer Drugs. 2022 Jan 01;33(1):e813-e817. doi: 10.1097/CAD.0000000000001228. PMID: 34459465; PMCID: PMC8670335.
Copy Download .nbib Format: NLM
GL3, a Novel 4β-Anilino-4'-O-Demethyl-4-Desoxypodophyllotoxin Analog, Traps Topoisomerase II Cleavage Complexes and Exerts Anticancer Activities.

Translational oncology

Yang XC, Qian SJ, Wang L, Liao SD, Cao J, Hu YZ, He QJ, Zhu H, Yang B.
PMID: 23418619
Transl Oncol. 2013 Feb;6(1):75-82. doi: 10.1593/tlo.12343. Epub 2013 Feb 01.

A novel VP-16 derivative, 4β-[N -(4‴-acetyloxyl-phenyl-1‴-carbonyl)-4″-aminoanilino]-4'-O-demethyl-4-desoxypodophyllotoxin (GL3), displayed a wide range of cytotoxicity in a panel of human tumor cell lines, with half-maximal inhibitory concentration (IC(50)) values ranging from 0.82 to 4.88 µM, much less than that of VP-16...

Cite
Yang XC, Qian SJ, Wang L, et al. GL3, a Novel 4β-Anilino-4'-O-Demethyl-4-Desoxypodophyllotoxin Analog, Traps Topoisomerase II Cleavage Complexes and Exerts Anticancer Activities. Transl Oncol. 2013;6(1):75-82doi: 10.1593/tlo.12343.
Yang, X. C., Qian, S. J., Wang, L., Liao, S. D., Cao, J., Hu, Y. Z., He, Q. J., Zhu, H., & Yang, B. (2013). GL3, a Novel 4β-Anilino-4'-O-Demethyl-4-Desoxypodophyllotoxin Analog, Traps Topoisomerase II Cleavage Complexes and Exerts Anticancer Activities. Translational oncology, 6(1), 75-82. https://doi.org/10.1593/tlo.12343
Yang, Xiao-Chun, et al. "GL3, a Novel 4β-Anilino-4'-O-Demethyl-4-Desoxypodophyllotoxin Analog, Traps Topoisomerase II Cleavage Complexes and Exerts Anticancer Activities." Translational oncology vol. 6,1 (2013): 75-82. doi: https://doi.org/10.1593/tlo.12343
Yang XC, Qian SJ, Wang L, Liao SD, Cao J, Hu YZ, He QJ, Zhu H, Yang B. GL3, a Novel 4β-Anilino-4'-O-Demethyl-4-Desoxypodophyllotoxin Analog, Traps Topoisomerase II Cleavage Complexes and Exerts Anticancer Activities. Transl Oncol. 2013 Feb;6(1):75-82. doi: 10.1593/tlo.12343. Epub 2013 Feb 01. PMID: 23418619; PMCID: PMC3573656.
Copy Download .nbib Format: NLM
Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: A case report and literature review.

Oncology letters

Shi J, Ni Y, Li J, Qiu H, Miao K.
PMID: 26137042
Oncol Lett. 2015 May;9(5):2208-2210. doi: 10.3892/ol.2015.3043. Epub 2015 Mar 16.

The current study presents the case of a 78-year-old male with concurrent chronic neutrophilic leukemia (CNL) and multiple myeloma (MM) who developed acute myeloid leukemia after two years of treatment with hydroxyurea, cyclophosphamide, prednisone and thalidomide. The patient presented...

Cite
Shi J, Ni Y, Li J, et al. Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: A case report and literature review. Oncol Lett. 2015;9(5):2208-2210doi: 10.3892/ol.2015.3043.
Shi, J., Ni, Y., Li, J., Qiu, H., & Miao, K. (2015). Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: A case report and literature review. Oncology letters, 9(5), 2208-2210. https://doi.org/10.3892/ol.2015.3043
Shi, Jinning, et al. "Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: A case report and literature review." Oncology letters vol. 9,5 (2015): 2208-2210. doi: https://doi.org/10.3892/ol.2015.3043
Shi J, Ni Y, Li J, Qiu H, Miao K. Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: A case report and literature review. Oncol Lett. 2015 May;9(5):2208-2210. doi: 10.3892/ol.2015.3043. Epub 2015 Mar 16. PMID: 26137042; PMCID: PMC4467349.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 20 entries